Mitomycin C Treatment for Conjunctival—Corneal Intraepithelial Neoplasia: A Multicenter Experience

doi:10.1016/S0161-6420(97)30055-4

Ophthalmology

Volume 104, Issue 12, December 1997, Pages 2085-2093

https://doi.org/10.1016/S0161-6420(97)30055-4 Get rights and content

Objective: The purpose of the study is to evaluate the efficacy and risks of topical mitomycin C (MMC) for conjunctival-corneal intraepithelial neoplasia (CCIN).

Design: The study design was a clinical case series of CCIN.

Participants: Seventeen patients, 16 with biopsy-confirmed CCIN and 1 with invasive squamous cell carcinoma (SCC), were included in the study.

Intervention: Patients received topical drops of MMC 0.02% to 0.04% four times daily from 7 to 28 days. Retreatment was done in cases of lesion recurrence.

Main Outcome Measures: The size of the CCIN before and after the treatment and ocular complications post-MMC application were evaluated.

Results: Ten patients remained disease-free after one course of MMC application. In one case, residual CCIN remained very small without regrowth. In the one patient with invasive SCC and in five patients with CCIN, regrowth occurred within 6 months of the first treatment. After retreatment, invasive SCC and CCIN in an additional two patients were eradicated. In two cases, although the size of the lesions decreased after two and three applications of MMC, regrowth occurred, and the CCIN returned to its original size. In the final case, limited recurrence has occurred and no retreatment has been done. The complications of MMC use included mild-to-moderate conjunctival hyperemia and mild allergy, which resolved after discontinuation of the treatment. Severe pain manifested when treatment was longer than 14 days.

Conclusions: Application of topical MMC is an efficient treatment for most but not all cases of CCIN.

References (23)

JC Erie et al.
Conjunctival and corneal intraepithelial and invasive neoplasia
Ophthalmology
(1986)
GO III Waring et al.
Clinical and pathologic description of 17 cases of corneal intraepithelial neoplasia
Am J Ophthalmol
(1984)
FT Fraunfelder et al.
Management of intraepithelial conjunctival tumors and squamous cell carcinomas
Am J Ophthalmol
(1983)
D Elkon et al.
The use of strontium-90 in the treatment of carcinoma in situ of the conjunctiva
Am J Ophthalmol
(1979)
G Singh et al.
Mitomycin eye drops as treatment for pterygium
Ophthalmology
(1988)
S Hayasaka et al.
Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium
Am J Ophthalmol
(1988)
SS. Palmer
Mitomycin as adjunct chemotherapy with trabeculectomy
Ophthalmology
(1991)
J Frucht-Pery et al.
Mitomycin C therapy for corneal intraepithelial neoplasia
Am J Ophthalmol
(1994)
J Frucht-Pery et al.
Intraoperative application of topical mitomycin C for pterygium surgery
Ophthalmology
(1996)
J Frucht-Pery et al.
The use of low dose mitomycin C for prevention of recurrent pterygium
Ophthalmology
(1994)

H Ando et al.

Inhibition of corneal epithelial wound healing. A comparative study of mitomycin C and 5-fluorouracil

Ophthalmology

(1992)

Cited by (169)

Personalized treatment concepts in extraocular cancer
2024, Advances in Ophthalmology Practice and Research
The periocular skin is neoplasms-prone to various benign and malignant. Periocular malignancies are more aggressive and challenging to cure and repair than those in other skin areas. In recent decades, immunotherapy has significantly advanced oncology, allowing the autoimmune system to target and destroy malignant cells. Skin malignancies, especially periocular tumors, are particularly sensitive to immunotherapy. This technique has dramatically impacted the successful treatment of challenging tumors.
Extraocular cancers, including eyelid (basal cell carcinoma, squamous cell carcinoma, melanoma, merkel cell carcinoma), conjunctival tumors (conjunctival melanoma, ocular surface squamous neoplasia) and other rare tumors, are unique and challenging clinical situations. Several genetic alterations associated with the pathogenesis of these diseases have been identified, and molecular mechanism are essential for the development of the immunotherapy agents, such as Hedgehog pathway inhibitors (vismodegib and sonidegib) for basal cell carcinoma, BRAF/MEK inhibitors (vemurafenib, dabrafenib, and encorafenib) for melanoma, and immune checkpoint inhibitors (Avelumab, pembrolizumab) for Merkel cell carcinoma.
The optimal treatment for periocular skin cancer depends on the type and size of the tumor and whether it involves orbital and adnexal structures. Adjuvant and neoadjuvant therapy with chemotherapy-targeted therapies and immune checkpoint inhibitors should be considered based on tumor type, tumor molecular profile, expected response rate, and candidacy for systemic treatment.
Topical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment
2024, Asia-Pacific Journal of Ophthalmology
Ocular surface squamous neoplasia (OSSN) is a spectrum of malignancies that generally includes conjunctival intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC). OSSN can be treated with topical therapies including interferon α-2b (IFN), mitomycin C (MMC), or 5-fluorouracil 1% (5FU). Recently, due to unavailability of IFN and toxicity associated with MMC, therapy has shifted towards 5FU.
Herein, we compare the use of 5FU 1% as a primary versus (vs) secondary treatment regimen in eyes with moderate to extensive OSSN.
Retrospective cohort study of 73 consecutive patients with unilateral moderate to extensive OSSN treated at a single tertiary ocular oncology center from 2016 to 2023. Mean follow up time was 478.2 days overall, with 283.0 days for primary 5FU group and 860.3 days for secondary 5FU group.
Topical 5FU 1% 4 times daily for 2 weeks with option for 2-weekly extension until tumor control, either as primary treatment or as secondary treatment to surgical resection, topical IFN or topical MMC, or cryotherapy.
Outcome measures included tumor response, need for additional surgery, complications, and visual outcomes.
A comparison (primary vs secondary treatment) revealed no difference in mean tumor basal dimension (19.6 vs 17.2 mm, P = 0.46), thickness (3.7 vs 3.4 mm, P = 0.64), or tumor extent (4.4 vs 4.5 clock hours, P = 0.92). The primary treatment group showed greater complete tumor control (77% vs 38%, P = 0.04). Multivariable analysis comparison (primary vs secondary treatment) showed primary treatment more likely to achieve complete tumor control (P = 0.01). There was no difference in the complication rate from 5FU treatment between the groups. There was no difference in visual outcome, and no tumor-related metastasis (0%) or death (0%).
Topical 5FU 1% is efficacious and safe as a primary or secondary treatment for moderate to extensive OSSN. Tumors treated with primary 5FU 1% demonstrated more complete resolution. In patients with moderate to extensive OSSN, primary treatment with topical 5FU 1% may be warranted.
Effects of corneal epithelial superficial keratectomy in patients with focal limbal stem cell disease
2022, American Journal of Ophthalmology Case Reports
Citation Excerpt :
These severe cases are a contra-indication for our technique. According to the principle of starting with the least invasive treatment, topical eye drops such as mitomycin C25 should have been performed first, but we did not try mitomycin C prior to keratectomy because there was a report that its use can, in fact, induce LSC disorder.26 A further limitation is that long-term survival has not been assured, as the longest follow-up period was 3 years (Case 2).
Irregular corneal epithelium in limbal stem cell disease can cause visual acuity to deteriorate substantially when it reaches the pupil. In this case series, we assessed the effectiveness of simple corneal epithelial superficial keratectomy in improving visual acuity in patients with irregular corneal epithelium in focal limbal stem cell disease covering the visual axis.
We performed simple corneal epithelial superficial keratectomy in four patients (five eyes) with irregular corneal epithelium covering the visual axis. The main outcome measures were best-corrected visual acuity, slit lamp findings with fluorescein staining, anterior segment optical coherence tomography and histopathology. In all five eyes, slit lamp findings showed uneven fluorescein staining in a spiral pattern, with impaired corneal epithelial smoothness and visual disturbance. We removed the irregular epithelium in all five eyes. Visual acuity in all the eyes was improved immediately after surgery, and good visual acuity and stable epithelium were maintained for the duration of the observation periods. Hematoxylin and eosin staining showed, normal squamous and columnar epithelial cells. Goblet cells were not detected.
Corneal epithelial superficial keratectomy can lead to a pathological diagnosis by examining the removed epithelial tissues, and result in excellent therapeutic outcomes in focal limbal stem cell disease reaching the pupil.
Canalicular Stenosis Secondary to Chemotherapeutic Agents
2021, Advances in Ophthalmology and Optometry
Citation Excerpt :
MMC is a chemotherapeutic antibiotic that cross-links DNA base pairs adenine and guanine, inhibiting the synthesis of DNA. It has been used to treat several ocular conditions, including conjunctival corneal intraepithelial neoplasia [17], primary acquired melanoma [18], as well as glaucoma [19] and pterygium surgeries [3]. Punctal-canalicular stenosis secondary to MMC was first described in 2003 in a case report of a 62-year-old woman who was treated with MMC for corneal epithelial dysplasia [20].
Ocular surface complications of local anticancer drugs for treatment of ocular tumors
2021, Ocular Surface
Citation Excerpt :
Superficial keratitis is often observed in eyes treated with local anticancer drugs, and can be attributed to increased inflammatory response induced by drugs, such as IFN-α and imiquimod, that act by boosting the immune system [58,61,70,71,123–125]. Contact dermatitis and allergic lid reaction including edema, blepharitis, ectropion, erythema, eyelid inflammation and blepharospasm have been reported in eyes administered topical MMC (10–34%) [16,20,21,24,26,27] and topical 5-FU (5–49.2%) [34,37–40,43,44]. Punctal and canalicular obstruction leading to epiphora are well-known complications associated with many systemic chemotherapies.
Local chemotherapy is increasingly used, either in combination with surgery or as monotherapy, for management of ocular tumors. Yet many of the local chemotherapeutic agents used for ocular tumors are cytotoxic drugs that are frequently associated with toxicities in normal ocular tissues. Understanding and managing these side effects are important because they affect treatment tolerability, outcome and quality of vision. Herein, we review local anticancer drugs administered for the treatment of ocular tumors, with an emphasis on their toxicities to the ocular surface, adnexa and lacrimal drainage system. We provide the underlying mechanisms and management strategies for the ocular side effects. Recent innovations in anticancer immunotherapy and ocular drug delivery systems also are discussed as new potential therapeutic modalities for alleviation of side effects.
The treatment of recurrent conjunctival and corneal intraepithelial neoplasia with interferon alfa-2b and retinoic acid: ~9 years’ follow-up on tumor control
2020, Ocular Surface
To evaluate the long-term follow-up of recurrent conjunctival and corneal intraepithelial neoplasia (CCIN) treated with combination topical interferon alfa-2b and retinoic acid (I/RA).
Our study represents a retrospective observational interventional series of 82 eyes from 82 patients from a single institution, reviewed for CCIN. All were administered topical interferon alfa-2b 1 million IU/mL QID and retinoic acid 0.01% every other day. Patients had been diagnosed by biopsy. A Kaplan-Meier survival analysis, Wilcoxon signed-rank test and a multivariate logistic regression were statistical tests used to correlate recurrence with patient and tumor variables.
79 eyes assessed for CCIN diagnoses and treated with I/RA achieved tumor resolution. The median tumor-free follow-up was ~109.1 months with a median time to resolution being ~2.8 months. Our median treatment duration was ~11.3 months. The greatest difference in the mean total residual tumor size was identified between Months 0–1 [-7.63 mm²]. The difference in mean total residual tumor size remained significant till 36-months. A statistically significant correlation with recurrence was identified for biopsy type [OR 0.138]. 6 patients experienced papillary conjunctivitis which resolved with dosage reduction.
Combination I/RA was effective in treating CCIN lesions with few transient side effects. The combination of retinoids and interferons may represent a viable topical therapeutic agent with an extended tumor-free follow-up and a large proportion of our study's patients achieving >10 year's tumor-free follow-up. Our treatment duration is long, but by cost-comparing surgical against medical interventions, topical I/RA may serve as a safe and effective alternative.

View all citing articles on Scopus

: Presented as a paper at the American Academy of Ophthalmology Annual Meeting, Chicago, October 1996.

: The authors have no proprietary interest in the development or marketing of this or a competing drug.

View full text

Mitomycin C Treatment for Conjunctival—Corneal Intraepithelial Neoplasia: A Multicenter Experience

Ophthalmology

Am J Ophthalmol

Am J Ophthalmol

Am J Ophthalmol

Ophthalmology

Am J Ophthalmol

Ophthalmology

Am J Ophthalmol

Ophthalmology

Ophthalmology

Ophthalmology